Market Overview

Veristat is Recognized on the Inc. 5000 List of America's Fastest-Growing Private Companies for the 4th Consecutive Year

Share:

Veristat's Continued Innovation of Its Clinical Development
Strategies and Services Allow the Company to Execute High Quality Trials
That Reach Regulatory Approval.

Veristat,
a full service Clinical Research Organization (CRO), proudly announces
its recognition once again by Inc. Magazine as one of the 5000
fastest-growing private companies in the United States. Since its first
appearance on the list in 2015, Veristat has accelerated its growth in
size, geographic reach and ability to successfully guide clinical trials
through the development process to regulatory approval.

"Veristat's ability to achieve this national recognition and to remain
on this list for 4 consecutive years highlights our sustainability,
innovation and unfaltering commitment to consistently delivering the
highest quality clinical development and regulatory submission services
to our clients," stated Patrick Flanagan, Chief Executive Officer at
Veristat. "The meaningful impact that our teams provide to our clients
and to lives of the patients their programs benefit is astounding. In
2018, our teams supported five regulatory submissions that were
submitted to the US Food & Drug Administration (FDA) and Health Canada.
Four of the submission projects which we previously supported received
approval this year."

Veristat strives to work collaboratively with biotechnology and
pharmaceutical companies throughout the entire clinical development life
cycle: from trial design all the way to regulatory approval. The Company
plans to embark on an even more aggressive growth strategy in the coming
year to further improve and expand our capabilities into new services
offerings and geographies to pro-actively address the needs of our
growing client base.

Inc. Magazine has been ranking the top 5000 fastest-growing private
companies since 1982. Earning a spot on this list is a milestone
achievement. The list represents risk-takers and entrepreneurs that
build something great from the ground up, a feat many cannot say they
have accomplished. According to INC.com, this year's fastest-growing
companies in America are a force, notching collective revenue of more
than $206.2 billion in 2017 and three-year revenue growth rates that
reach 75,661 percent. To learn more, view the 2018
Inc. 5000 List
.

About Veristat:

Veristat
is a clinical research partner focused on supporting biopharmaceutical
firms as they advance their therapies through the clinical development
and regulatory submission process. Our work delivers meaningful clinical
impact and our regulatory submission expertise is unrivaled in our
industry. Veristat teams have supported over 70 regulatory submission
projects that have resulted in more than 40 submission approvals to date
from various regulatory agencies around the world. We work
collaboratively with clients to create a personalized project team of
collaborative problem-solvers based on their therapy area and clinical
development needs. Veristat aims is to propel even the most complex
submissions to successful regulatory conclusions so that new therapies
become available to improve and save lives. For more information on our
impactful strategic consulting, data analysis, clinical trial management
or regulatory submission expertise, visit www.veristat.com.

View Comments and Join the Discussion!